R&D channel feed

San­thera rene­go­ti­ates mile­stone pay­ment, in­creas­es liq­uid­i­ty run­way in­to 2023 pend­ing NDA fil­ing

4 years ago
Financing

Roche wa­gers $180M in quick cash on a can­di­date for best-in-class tu­mor tar­get­ing drug

4 years ago

FDA lifts hold on Leg­end Biotech's fol­low-up CAR-T tar­get­ing CD4+

4 years ago
FDA+

Trail­ing As­traZeneca in lu­pus, Bris­tol My­ers looks to push TYK2 drug in­to PhI­II tri­als

4 years ago

Sage and Bio­gen build out case for de­pres­sion drug as it pass­es PhI­II test in post­par­tum women

4 years ago

Sanofi earns break­through nod in he­mo­phil­ia A as it con­tin­ues to play catch-up with Roche's Hem­li­bra

4 years ago
FDA+

Re­search re­vamp: UK calls on clin­i­cal tri­al spon­sors to shut down tri­als that aren't vi­able

4 years ago
Coronavirus

Swedish biotech crum­bles in face of PhII fail­ure of prostate can­cer vac­cine

4 years ago

Once again, the FDA is de­lay­ing Bio­Marin’s he­mo­phil­ia A quest as gene ther­a­py frets sim­mer

4 years ago

TG Ther­a­peu­tics gets 3-month punt from FDA for stand­alone BLA in af­ter­math of Ukoniq + ad­comm with­draw­al

4 years ago
FDA+

Tran­si­tion to new Eu­ro­pean clin­i­cal tri­als in­fo sys­tem starts slow­ly

4 years ago

AS­CO ab­stracts mint some ear­ly win­ners, but Io­vance, Spring­Works get hit by mas­sive loss­es

4 years ago

Keep­ing pres­sure on Am­gen, Mi­rati draws mixed re­views on lat­est cut of KRAS da­ta

4 years ago

Roche's CD20xCD3 does­n't beat Gen­mab at ORR, but sets bar for CR da­ta on lym­phoma drug

4 years ago
Pharma

In search of elu­sive NASH break­through, Pfiz­er spot­lights com­bo ap­proach

4 years ago

Say­ing good­bye to R&D chief, Flag­ship-backed Ax­cel­la drops PhII pro­gram as it fo­cus­es on long Covid, NASH

4 years ago
People
Coronavirus

Plan­ning ahead for crowd­ed ul­cer­a­tive col­i­tis mar­ket, Pfiz­er spells out PhI­II da­ta on $6.7B Are­na drug

4 years ago

Pfiz­er spin­out Spring­Works will ship its first drug to the FDA be­fore year’s end with PhI­II win

4 years ago

A new era of treat­ment: How bio­mark­ers are chang­ing the way we think about can­cer

4 years ago
In Focus

Blam­ing Covid dis­rup­tion, sup­ply short­ages, mi­cro­cap biotech hits the brakes on cell ther­a­py tri­al

4 years ago
Cell/Gene Tx

Lil­ly's mirik­izum­ab, once a con­tender for pso­ri­a­sis, bol­sters case for UC in­di­ca­tion in main­te­nance tri­al da­ta read­out

4 years ago
Pharma

Idor­sia claims PhI­II win for hy­per­ten­sion drug at cen­ter of $230M J&J deal

4 years ago

'Xeno­trans­plan­ta­tion is com­ing': New NE­JM pa­per gives de­tailed look in­to 2 pig-to-hu­man kid­ney trans­plant cas­es

4 years ago

One tri­al down, one to go as Con­cert Phar­ma­ceu­ti­cals tunes up PhI­II win for alope­cia drug

4 years ago
First page Previous page 134135136137138139140 Next page Last page
A service from the Financial Times